The vaccine being developed by Monash/Doherty and manufactured by IDT is only for phase 1/2 trials, which will look at safety and immunogenicity (ie antibody levels in the blood). No matter how good the immunogenicity results look like, this doesn't tell us about the efficacy of the vaccine, which need large-scale real-world trials (phase 3, around 30,000 people, ideally unvaccinated, so in a country where vaccine rates are still low).
They would need to find a big pharmaceutical company to partner with them to do these sorts of trials, as universities and academic insitutions don't have the money to organise and run these.
So I would be very doubtful that results will be available before the end of 2022, and that this vaccine will be able to compete with any existing ones for at least a few years, sadly.
So while IDT could possibly be contracted to produce vaccine for the phase 3 trial, I highly doubt they will be doing any commercial manufacture of covid mRNA vaccine now for the next few years, unfortunately.
- Forums
- ASX - By Stock
- IDT
- Ann: Trading Halt
Ann: Trading Halt, page-106
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IDT (ASX) to my watchlist
(20min delay)
|
|||||
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.43M |
Open | High | Low | Value | Volume |
12.0¢ | 12.0¢ | 11.5¢ | $28.31K | 245.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 18704 | 11.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.0¢ | 367359 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 18704 | 0.115 |
11 | 703665 | 0.110 |
4 | 509533 | 0.105 |
2 | 200500 | 0.100 |
1 | 30000 | 0.099 |
Price($) | Vol. | No. |
---|---|---|
0.120 | 367359 | 5 |
0.125 | 200000 | 3 |
0.130 | 151481 | 3 |
0.140 | 471150 | 4 |
0.145 | 152627 | 2 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
IDT (ASX) Chart |